- Home
- INBX vs MMI Comparison
INBX vs MMI Comparison
Compare INBX & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INBX | MMI |
|---|---|---|
| Founded | 2010 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.7M | 1.1B |
| IPO Year | 2024 | 2013 |
Fundamental Metrics
Financial Performance| Metric | INBX | MMI |
|---|---|---|
| Price | $103.07 | $28.45 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 3 | 2 |
| Target Price | ★ $150.00 | $28.00 |
| AVG Volume (30 Days) | ★ 442.3K | 241.6K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.78% |
| EPS Growth | N/A | ★ 84.38 |
| EPS | N/A | ★ N/A |
| Revenue | $1,300,000.00 | ★ $719,700,000.00 |
| Revenue This Year | N/A | $14.04 |
| Revenue Next Year | N/A | $11.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $12.80 | $24.43 |
| 52 Week High | $155.29 | $33.62 |
Technical Indicators
Market Signals| Indicator | INBX | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 49.39 |
| Support Level | $99.20 | $27.12 |
| Resistance Level | $153.14 | $28.56 |
| Average True Range (ATR) | 11.61 | 0.76 |
| MACD | -3.13 | -0.17 |
| Stochastic Oscillator | 7.41 | 17.48 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.